Stephen Hoge sold $12M of MRNA
President at Moderna, Inc.. 80,575 shares at an average of $145.10, traded Sep 14, 2026, filed Sep 16, 2026.
Score components
- +20RolePresident
- +25Trade size$11.7M at market
- 0Share of holdings soldSold 5.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001682852-26-000176, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | MOption exercise Common Stock10b5-1 | +76,453 | $12.21 | $933k | 1,566,152 | 26 d ago |
| Sep 14, 2026 | SOpen-market sale Common Stock10b5-1 | -40,294 | $144.13 | $5.8M | 1,525,858 | 26 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +76,452 | $12.21 | $933k | 1,602,310 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -40,281 | $146.07 | $5.9M | 1,562,029 | 26 d ago |
| Sep 14, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -76,453 | $0.00 | $0 | 382,262 | 26 d ago |
| Sep 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -76,452 | $0.00 | $0 | 305,810 | 26 d ago |
Related signals
Other insiders at Moderna, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Moderna, Inc. | James M Mock Chief Financial Officer | $4.7M 34,836 shares | -37% | |
| 13Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $486k 3,471 shares | -4% | |
| 49Moderate | Moderna, Inc. | Noubar Afeyan director | $703k 23,853 shares | -86% | |
| 8Weak | Moderna, Inc. | Abbas Hussain director | $14k 504 shares | -25% | |
| 5Weak | Moderna, Inc. | Abbas Hussain director | $8,736 312 shares | -35% | |
| 50Moderate | MRNAbuy Moderna, Inc. | Stephane Bancel Chief Executive Officer | $5.0M 160,314 shares | +2% | |
| 0Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $24k 529 shares | -3% | |
| 0Weak | Moderna, Inc. | Stephen Hoge President | $14k 314 shares | -0% | |
| 0Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $4,849 112 shares | -1% | |
| 0Weak | Moderna, Inc. | Stephen Hoge President | $12k 291 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.